

# Roberta Diaz Brinton

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1653387/roberta-diaz-brinton-publications-by-citations.pdf>  
**Version:** 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.  
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

83 papers	6,682 citations	43 h-index	81 g-index
94 ext. papers	7,740 ext. citations	6.4 avg, IF	6.38 L-index

#	Paper	IF	Citations
83	Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2009</b> , 106, 14670-5	11.5	639
82	Progesterone receptors: form and function in brain. <i>Frontiers in Neuroendocrinology</i> , <b>2008</b> , 29, 313-39	8.9	434
81	Age, APOE and sex: Triad of risk of Alzheimer's disease. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , <b>2016</b> , 160, 134-47	5.1	266
80	Estrogen: a master regulator of bioenergetic systems in the brain and body. <i>Frontiers in Neuroendocrinology</i> , <b>2014</b> , 35, 8-30	8.9	254
79	The healthy cell bias of estrogen action: mitochondrial bioenergetics and neurological implications. <i>Trends in Neurosciences</i> , <b>2008</b> , 31, 529-37	13.3	245
78	The neurosteroid allopregnanolone promotes proliferation of rodent and human neural progenitor cells and regulates cell-cycle gene and protein expression. <i>Journal of Neuroscience</i> , <b>2005</b> , 25, 4706-18	6.6	222
77	Allopregnanolone reverses neurogenic and cognitive deficits in mouse model of Alzheimer's disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2010</b> , 107, 6498-503	11.5	220
76	Mechanism of estrogen-mediated neuroprotection: regulation of mitochondrial calcium and Bcl-2 expression. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2003</b> , 100, 2842-7	11.5	217
75	Estrogen receptor subtypes alpha and beta contribute to neuroprotection and increased Bcl-2 expression in primary hippocampal neurons. <i>Brain Research</i> , <b>2004</b> , 1010, 22-34	3.7	211
74	Estrogen-induced plasticity from cells to circuits: predictions for cognitive function. <i>Trends in Pharmacological Sciences</i> , <b>2009</b> , 30, 212-22	13.2	200
73	Progesterone and estrogen regulate oxidative metabolism in brain mitochondria. <i>Endocrinology</i> , <b>2008</b> , 149, 3167-75	4.8	198
72	Early decline in glucose transport and metabolism precedes shift to ketogenic system in female aging and Alzheimer's mouse brain: implication for bioenergetic intervention. <i>PLoS ONE</i> , <b>2013</b> , 8, e79977	7.7	146
71	Minireview: translational animal models of human menopause: challenges and emerging opportunities. <i>Endocrinology</i> , <b>2012</b> , 153, 3571-8	4.8	137
70	Estradiol in vivo regulation of brain mitochondrial proteome. <i>Journal of Neuroscience</i> , <b>2007</b> , 27, 14069-76	7.6	134
69	Investigative models for determining hormone therapy-induced outcomes in brain: evidence in support of a healthy cell bias of estrogen action. <i>Annals of the New York Academy of Sciences</i> , <b>2005</b> , 1052, 57-74	6.5	126
68	Neuroprotective and neurotrophic efficacy of phytoestrogens in cultured hippocampal neurons. <i>Experimental Biology and Medicine</i> , <b>2002</b> , 227, 509-19	3.7	126
67	Mitochondria as therapeutic targets of estrogen action in the central nervous system. <i>CNS and Neurological Disorders</i> , <b>2004</b> , 3, 297-313		119

66	2-Deoxy-D-glucose treatment induces ketogenesis, sustains mitochondrial function, and reduces pathology in female mouse model of Alzheimer's disease. <i>PLoS ONE</i> , <b>2011</b> , 6, e21788	3.7	114
65	Sex and Race Differences in the Association Between Statin Use and the Incidence of Alzheimer Disease. <i>JAMA Neurology</i> , <b>2017</b> , 74, 225-232	17.2	110
64	Altered brain energetics induces mitochondrial fission arrest in Alzheimer's Disease. <i>Scientific Reports</i> , <b>2016</b> , 6, 18725	4.9	108
63	Estrogen regulation of glucose metabolism and mitochondrial function: therapeutic implications for prevention of Alzheimer's disease. <i>Advanced Drug Delivery Reviews</i> , <b>2008</b> , 60, 1504-11	18.5	107
62	Evidence for benefit of statins to modify cognitive decline and risk in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , <b>2017</b> , 9, 10	9	104
61	Sex differences in Alzheimer risk: Brain imaging of endocrine vs chronologic aging. <i>Neurology</i> , <b>2017</b> , 89, 1382-1390	6.5	104
60	Decline in mitochondrial bioenergetics and shift to ketogenic profile in brain during reproductive senescence. <i>Biochimica Et Biophysica Acta - General Subjects</i> , <b>2010</b> , 1800, 1121-6	4	101
59	Therapeutic potential of neurogenesis for prevention and recovery from Alzheimer's disease: allopregnanolone as a proof of concept neurogenic agent. <i>Current Alzheimer Research</i> , <b>2006</b> , 3, 185-90	3	101
58	Allopregnanolone restores hippocampal-dependent learning and memory and neural progenitor survival in aging 3xTgAD and nonTg mice. <i>Neurobiology of Aging</i> , <b>2012</b> , 33, 1493-506	5.6	98
57	17 $\beta$ -Estradiol regulates insulin-degrading enzyme expression via an ER $\alpha$ /PI3-K pathway in hippocampus: relevance to Alzheimer's prevention. <i>Neurobiology of Aging</i> , <b>2011</b> , 32, 1949-63	5.6	97
56	White Matter Lipids as a Ketogenic Fuel Supply in Aging Female Brain: Implications for Alzheimer's Disease. <i>EBioMedicine</i> , <b>2015</b> , 2, 1888-904	8.8	92
55	The women's health initiative estrogen replacement therapy is neurotrophic and neuroprotective. <i>Neurobiology of Aging</i> , <b>2000</b> , 21, 475-96	5.6	90
54	Allopregnanolone promotes regeneration and reduces $\beta$ -amyloid burden in a preclinical model of Alzheimer's disease. <i>PLoS ONE</i> , <b>2011</b> , 6, e24293	3.7	89
53	Ovarian hormone loss induces bioenergetic deficits and mitochondrial $\beta$ -amyloid. <i>Neurobiology of Aging</i> , <b>2012</b> , 33, 1507-21	5.6	87
52	Advances and challenges in the prevention and treatment of Alzheimer's disease. <i>Pharmaceutical Research</i> , <b>1998</b> , 15, 386-98	4.5	84
51	Shift in brain metabolism in late onset Alzheimer's disease: implications for biomarkers and therapeutic interventions. <i>Molecular Aspects of Medicine</i> , <b>2011</b> , 32, 247-57	16.7	78
50	Allopregnanolone as regenerative therapeutic for Alzheimer's disease: translational development and clinical promise. <i>Progress in Neurobiology</i> , <b>2014</b> , 113, 40-55	10.9	73
49	Autoimmune Disease in Women: Endocrine Transition and Risk Across the Lifespan. <i>Frontiers in Endocrinology</i> , <b>2019</b> , 10, 265	5.7	70

48	WHI and WHIMS follow-up and human studies of soy isoflavones on cognition. <i>Expert Review of Neurotherapeutics</i> , <b>2007</b> , 7, 1549-64	4.3	70
47	A select combination of clinically relevant phytoestrogens enhances estrogen receptor beta-binding selectivity and neuroprotective activities in vitro and in vivo. <i>Endocrinology</i> , <b>2009</b> , 150, 770-83	4.8	68
46	Perimenopause and emergence of an Alzheimer's bioenergetic phenotype in brain and periphery. <i>PLoS ONE</i> , <b>2017</b> , 12, e0185926	3.7	62
45	Estrogen regulation of mitochondrial bioenergetics: implications for prevention of Alzheimer's disease. <i>Advances in Pharmacology</i> , <b>2012</b> , 64, 327-71	5.7	60
44	Increased Alzheimer's risk during the menopause transition: A 3-year longitudinal brain imaging study. <i>PLoS ONE</i> , <b>2018</b> , 13, e0207885	3.7	59
43	Ovariectomy induces a shift in fuel availability and metabolism in the hippocampus of the female transgenic model of familial Alzheimer's. <i>PLoS ONE</i> , <b>2013</b> , 8, e59825	3.7	52
42	Frontiers in therapeutic development of allopregnanolone for Alzheimer's disease and other neurological disorders. <i>Frontiers in Cellular Neuroscience</i> , <b>2014</b> , 8, 203	6.1	47
41	Preclinical analyses of the therapeutic potential of allopregnanolone to promote neurogenesis in vitro and in vivo in transgenic mouse model of Alzheimer's disease. <i>Current Alzheimer Research</i> , <b>2006</b> , 3, 11-7	3	44
40	Reversal of metabolic deficits by lipoic acid in a triple transgenic mouse model of Alzheimer's disease: a <sup>13</sup> C NMR study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2014</b> , 34, 288-96	7.3	38
39	Potentiation of brain mitochondrial function by S-equol and R/S-equol estrogen receptor selective phytoSERM treatments. <i>Brain Research</i> , <b>2013</b> , 1514, 128-41	3.7	37
38	Sex and Gender Driven Modifiers of Alzheimer's: The Role for Estrogenic Control Across Age, Race, Medical, and Lifestyle Risks. <i>Frontiers in Aging Neuroscience</i> , <b>2019</b> , 11, 315	5.3	37
37	ApoE4 Impairs Neuron-Astrocyte Coupling of Fatty Acid Metabolism. <i>Cell Reports</i> , <b>2021</b> , 34, 108572	10.6	33
36	Estrogen protection against mitochondrial toxin-induced cell death in hippocampal neurons: antagonism by progesterone. <i>Brain Research</i> , <b>2011</b> , 1379, 2-10	3.7	32
35	Allopregnanolone-induced rise in intracellular calcium in embryonic hippocampal neurons parallels their proliferative potential. <i>BMC Neuroscience</i> , <b>2008</b> , 9 Suppl 2, S11	3.2	32
34	Identifying postmenopausal women at risk for cognitive decline within a healthy cohort using a panel of clinical metabolic indicators: potential for detecting an at-Alzheimer's risk metabolic phenotype. <i>Neurobiology of Aging</i> , <b>2016</b> , 40, 155-163	5.6	32
33	Impact of Type 2 Diabetes and Postmenopausal Hormone Therapy on Incidence of Cognitive Impairment in Older Women. <i>Diabetes Care</i> , <b>2015</b> , 38, 2316-24	14.6	31
32	Requirements of a brain selective estrogen: advances and remaining challenges for developing a NeuroSERM. <i>Journal of Alzheimer's Disease</i> , <b>2004</b> , 6, S27-35	4.3	30
31	Hypermetabolic state in the 7-month-old triple transgenic mouse model of Alzheimer's disease and the effect of lipoic acid: a <sup>13</sup> C-NMR study. <i>Journal of Cerebral Blood Flow and Metabolism</i> , <b>2014</b> , 34, 1749-60	7.3	29

30	Allopregnanolone preclinical acute pharmacokinetic and pharmacodynamic studies to predict tolerability and efficacy for Alzheimer's disease. <i>PLoS ONE</i> , <b>2015</b> , 10, e0128313	3.7	28
29	Vasopressin-induced neurotrophism in cultured hippocampal neurons via V1 receptor activation. <i>Journal of Neurobiology</i> , <b>1994</b> , 25, 380-94		25
28	Targeting mitochondrial bioenergetics for Alzheimer's prevention and treatment. <i>Current Pharmaceutical Design</i> , <b>2011</b> , 17, 3474-9	3.3	24
27	Estrogen receptor $\alpha$ is a therapeutic target for promoting neurogenesis and preventing neurodegeneration. <i>Drug Development Research</i> , <b>2005</b> , 66, 103-117	5.1	23
26	Postmenopausal hormone therapy, type 2 diabetes mellitus, and brain volumes. <i>Neurology</i> , <b>2015</b> , 85, 1131-8	6.5	20
25	Data-driven identification of endophenotypes of Alzheimer's disease progression: implications for clinical trials and therapeutic interventions. <i>Alzheimer's Research and Therapy</i> , <b>2018</b> , 10, 4	9	20
24	Neuroendocrine aging precedes perimenopause and is regulated by DNA methylation. <i>Neurobiology of Aging</i> , <b>2019</b> , 74, 213-224	5.6	17
23	Statin therapy and risk of Alzheimer's and age-related neurodegenerative diseases. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2020</b> , 6, e12108	6	13
22	Transitions in metabolic and immune systems from pre-menopause to post-menopause: implications for age-associated neurodegenerative diseases. <i>F1000Research</i> , <b>2020</b> , 9,	3.6	12
21	Association Between Hormone-Modulating Breast Cancer Therapies and Incidence of Neurodegenerative Outcomes for Women With Breast Cancer. <i>JAMA Network Open</i> , <b>2020</b> , 3, e201541	10.4	12
20	Menopause impacts human brain structure, connectivity, energy metabolism, and amyloid-beta deposition. <i>Scientific Reports</i> , <b>2021</b> , 11, 10867	4.9	11
19	Epigenetics of the developing and aging brain: Mechanisms that regulate onset and outcomes of brain reorganization. <i>Neuroscience and Biobehavioral Reviews</i> , <b>2021</b> , 125, 503-516	9	11
18	Selective estrogen receptor modulators (SERM) for the brain: Recent advances and remaining challenges for developing a NeuroSERM. <i>Drug Development Research</i> , <b>2002</b> , 56, 380-392	5.1	10
17	Allopregnanolone Reverses Bioenergetic Deficits in Female Triple Transgenic Alzheimer's Mouse Model. <i>Neurotherapeutics</i> , <b>2020</b> , 17, 178-188	6.4	10
16	Sex-Related Differences in Brain Volumes and Cerebral Blood Flow Among Overweight and Obese Adults With Type 2 Diabetes: Exploratory Analyses From the Action for Health in Diabetes Brain Magnetic Resonance Imaging Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , <b>2020</b> , 75, 771-778	6.4	8
15	Neuroendocrinology: Oestrogen therapy affects brain structure but not function. <i>Nature Reviews Neurology</i> , <b>2016</b> , 12, 561-2	15	7
14	Allopregnanolone Promotes Neuronal and Oligodendrocyte Differentiation In Vitro and In Vivo: Therapeutic Implication for Alzheimer's Disease. <i>Neurotherapeutics</i> , <b>2020</b> , 17, 1813-1824	6.4	6
13	Mitochondria-Targeted Therapeutics for Alzheimer's Disease: The Good, the Bad, the Potential. <i>Antioxidants and Redox Signaling</i> , <b>2021</b> , 34, 611-630	8.4	6

12	Association between menopausal hormone therapy and risk of neurodegenerative diseases: Implications for precision hormone therapy. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2021</b> , 7, e12174	6	6
11	Drug therapies for chronic conditions and risk of Alzheimer's disease and related dementias: A scoping review. <i>Alzheimer's and Dementia</i> , <b>2021</b> , 17, 41-48	1.2	5
10	[P3025]: ALLOPREGNANOLONE, REGENERATIVE THERAPEUTIC FOR ALZHEIMER'S DISEASE: PHASE 1B/2A UPDATE <b>2017</b> , 13, P939-P940		3
9	Sex and APOE genotype differences related to statin use in the aging population. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2021</b> , 7, e12156	6	2
8	[F30401]: FUELING THE GLUCOSE-STARVED ALZHEIMER'S BRAIN: CATABOLISM OF WHITE MATTER IN THE BRAIN TO GENERATE KETONE BODIES <b>2017</b> , 13, P882-P883		1
7	Building a neuroscience legacy. <i>Journal of Neuroscience</i> , <b>2007</b> , 27, 11163-6	6.6	1
6	Association of Reproductive History With Brain MRI Biomarkers of Dementia Risk in Midlife. <i>Neurology</i> , <b>2021</b> , 97, e2328-e2339	6.5	1
5	Preventing Alzheimer's disease within reach by 2025: Targeted-risk-AD-prevention (TRAP) strategy. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , <b>2021</b> , 7, e12190	6	1
4	Endogenous and Exogenous Estrogen Exposures: How Women's Reproductive Health Can Drive Brain Aging and Inform Alzheimer's Prevention.. <i>Frontiers in Aging Neuroscience</i> , <b>2022</b> , 14, 831807	5.3	1
3	Effect of ApoE4 Genotype on the Association Between Metabolic Phenotype and Subclinical Atherosclerosis in Postmenopausal Women. <i>American Journal of Cardiology</i> , <b>2019</b> , 124, 1031-1037	3	0
2	Gonadal Hormones, Neurosteroids, and Clinical Progestins as Neurogenic Regenerative Agents: Therapeutic Implications <b>2011</b> , 281-303		
1	F2-01-01: TRANSITIONS OF THE AGING FEMALE BRAIN: WINDOW INTO UNDERLYING MECHANISMS OF LATE ONSET ALZHEIMER'S DISEASE <b>2018</b> , 14, P601-P602		